Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Ruth A Ettinger"'
Autor:
Jasper C Lin, Ruth A Ettinger, Jason T Schuman, Ai-Hong Zhang, Muhammad Wamiq-Adhami, Phuong-Cac T Nguyen, Shelley M Nakaya-Fletcher, Komal Puranik, Arthur R Thompson, Kathleen P Pratt
Publikováno v:
PLoS ONE, Vol 10, Iss 1, p e0116577 (2015)
The development of neutralizing anti-factor VIII (FVIII) antibodies complicates the treatment of many hemophilia A patients. The C-terminal C2 domain is a particularly antigenic FVIII region. A crystal structure of recombinant FVIII-C2 bound to an Fa
Externí odkaz:
https://doaj.org/article/9f01ce1acfea4daca262cfb00998c208
Autor:
Kenneth B Lewis, Richard J Hughes, Melinda S Epstein, Neil C Josephson, Christine L Kempton, Craig M Kessler, Nigel S Key, Tom E Howard, Rebecca Kruse-Jarres, Jeanne M Lusher, Christopher E Walsh, Raymond G Watts, Ruth A Ettinger, Kathleen P Pratt, PATH (Personalized Alternative Therapies for Haemophilia) Study Investigators
Publikováno v:
PLoS ONE, Vol 8, Iss 5, p e61120 (2013)
Evidence of antibody isotype/subtype switching may provide prognostic value regarding the state of immune responses to therapeutic proteins, e.g. anti-factor VIII (FVIII) antibodies that develop in many hemophilia A patients, clinically termed "inhib
Externí odkaz:
https://doaj.org/article/ed2b94404c024e57811b2da41995a2a6
Autor:
Ruth A. Ettinger, Joseph A. Liberman, Devi Gunasekera, Komal Puranik, Eddie A. James, Arthur R. Thompson, Kathleen P. Pratt
Publikováno v:
Blood Advances, Vol 2, Iss 4, Pp 309-322 (2018)
Abstract: Factor VIII (FVIII)–neutralizing antibodies (inhibitors) are a serious complication in hemophilia A (HA). The peptide FVIII2194-2213 contains an immunodominant HLA-DRA*01-DRB1*01:01 (DRB1*01:01)-restricted epitope recognized by CD4+ T-eff
Externí odkaz:
https://doaj.org/article/8cdfc0df3f83466e80e9f6064c811ebe
Publikováno v:
Biomedicines, Vol 9, Iss 2, p 202 (2021)
Islet antigen reactive T cells play a key role in promoting beta cell destruction in type 1 diabetes (T1D). Self-reactive T cells are typically deleted through negative selection in the thymus or deviated to a regulatory phenotype. Nevertheless, thos
Externí odkaz:
https://doaj.org/article/7c890dc89f1e40f0afcb075503213e18
Publikováno v:
Biomedicines, Vol 9, Iss 202, p 202 (2021)
Biomedicines
Biomedicines
Islet antigen reactive T cells play a key role in promoting beta cell destruction in type 1 diabetes (T1D). Self-reactive T cells are typically deleted through negative selection in the thymus or deviated to a regulatory phenotype. Nevertheless, thos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::839050e8fb31dea205922eb467c28d77
https://www.mdpi.com/2227-9059/9/2/202
https://www.mdpi.com/2227-9059/9/2/202
Autor:
Devi Gunasekera, Maochang Liu, Janice S. Withycombe, Eddie A. James, Richard J. Hughes, John C. Barrett, Shelley N Fletcher, Kathleen P. Pratt, Ruth A. Ettinger, Melinda S. Epstein, Dana C. Matthews
Publikováno v:
Blood. 126:895-904
African American hemophilia A (HA) patients experience a higher incidence of neutralizing antibodies (“inhibitors”) against factor VIII (FVIII) vis-à-vis Caucasian patients. Non-HA-causing non-synonymous single-nucleotide polymorphisms (ns-SNPs)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db9113cd3ff9bb259c9431458fc87ccc
https://doi.org/10.1182/blood-2014-09-599365
https://doi.org/10.1182/blood-2014-09-599365
Autor:
Daniel H. Moralejo, William R. A. Osborne, Richard A. Jensen, Jessica M. Fuller, Anne E. Kwitek, Brian Van Yserloo, Ruth A. Ettinger, Åke Lernmark, Elizabeth A. Rutledge
Publikováno v:
Life Sciences; 89(19-20), pp 748-754 (2011)
Aims: The Gimap gene family has been shown to be integral to T cell survival and development. A frameshift mutation in Gimap5, one of seven members of the Gimap family, results in lymphopenia and is a prerequisite for spontaneous type 1 diabetes (T1D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b2f993d19d4ba9e70e03202a6331fc5
https://doi.org/10.1016/j.lfs.2011.08.016
https://doi.org/10.1016/j.lfs.2011.08.016
Autor:
Ruth A. Ettinger, Jan Voorberg, S. D. Van Haren, Kathleen P. Pratt, Eddie A. James, Karin Fijnvandraat, William W. Kwok, Joseph A. Liberman
Publikováno v:
Journal of thrombosis and haemostasis, 9(4), 689-699. Wiley-Blackwell
Summary. Background: Development of neutralizing anti-factor (F)VIII antibodies (‘inhibitors’) is a serious clinical problem in hemophilia A. Increased inhibitor risk has been associated with certain FVIII missense substitutions, including R593C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bcaae37478bc34e36093c2afe02bbea
https://doi.org/10.1111/j.1538-7836.2011.04202.x
https://doi.org/10.1111/j.1538-7836.2011.04202.x
Publikováno v:
Blood. 114:1423-1428
The development of neutralizing antibodies (inhibitors) after factor VIII (FVIII) infusions is a serious complication that affects approximately one-quarter of hemophilia A patients who have access to replacement therapy. To investigate the different
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f1d8b7205f0f43979169435dbb11bdf
https://doi.org/10.1182/blood-2009-01-200725
https://doi.org/10.1182/blood-2009-01-200725
Publikováno v:
Journal of Thrombosis and Haemostasis. 5:2399-2407
Summary. Background: Antibodies that neutralize factor (F) VIII activity, clinically referred to as ‘inhibitors’, complicate the treatment of hemophilia A patients; current tolerance and bypass strategies are extremely costly and sometimes ineffe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e73918eaaf4ec01140bb784db6cbde1
https://doi.org/10.1111/j.1538-7836.2007.02762.x
https://doi.org/10.1111/j.1538-7836.2007.02762.x